- Home
- SWTX
as 02-21-2025 12:43pm EST
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | STAMFORD |
| Market Cap: | 3.0B | IPO Year: | 2019 |
| Target Price: | $70.83 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $28.21 - $61.70 | Next Earning Date: | 02-20-2025 |
| Revenue: | $191,589,000 | Revenue Growth: | 3417.33% |
| Revenue Growth (this year): | 3475.18% | Revenue Growth (next year): | 81.60% |
Stock Insider Trading Activity of SpringWorks Therapeutics Inc. (SWTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Islam Saqib | SWTX | Chief Executive Officer | Feb 14 '25 | Sell | $59.92 | 10,672 | $639,489.72 | 1,063,953 | |
| LYNCH DANIEL | SWTX | Director | Feb 14 '25 | Sell | $60.00 | 400 | $24,000.00 | 130,544 | |
| Pichl Daniel | SWTX | Chief People Officer | Feb 10 '25 | Sell | $54.81 | 29,750 | $1,617,329.10 | 50,762 | |
| Islam Saqib | SWTX | Chief Executive Officer | Feb 10 '25 | Sell | $53.30 | 48,000 | $2,558,236.80 | 1,063,953 | |
| Hambleton Julie | SWTX | Director | Feb 10 '25 | Sell | $53.01 | 13,774 | $730,206.57 | 4,095 | |
| LYNCH DANIEL | SWTX | Director | Feb 10 '25 | Sell | $54.54 | 175,000 | $9,530,351.23 | 130,544 | |
| Edris Badreddin | SWTX | Chief Operating Officer | Dec 3 '24 | Sell | $42.01 | 20,000 | $839,335.79 | 217,634 | |
| Islam Saqib | SWTX | Chief Executive Officer | Dec 2 '24 | Sell | $41.59 | 49,000 | $2,027,357.32 | 1,063,953 |
Latest SpringWorks Therapeutics Inc. News
SWTX Breaking Stock News: Dive into SWTX Ticker-Specific Updates for Smart Investing
GuruFocus.com
a day ago
SpringWorks Therapeutics Inc (SWTX) Q4 2024 Earnings Report Preview: What To Expect
GlobeNewswire
a day ago
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
PR Newswire
2 days ago
SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over
TipRanks
8 days ago
Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon
TipRanks
8 days ago
SpringWorks sets wholesale acquisition cost for Gomekli at $206.25 per mg
TipRanks
8 days ago
SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25
GlobeNewswire
10 days ago
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire
10 days ago
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Compare SWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SWTX SpringWorks Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.